These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 1321043)

  • 1. Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.
    Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Eur J Biochem; 1992 Jul; 207(1):239-46. PubMed ID: 1321043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
    Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret MC; Christophe J
    Eur J Biochem; 1992 Sep; 208(3):815-9. PubMed ID: 1327769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
    Robberecht P; Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Mol Pharmacol; 1992 Aug; 42(2):347-55. PubMed ID: 1325033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK.
    Cauvin A; Buscail L; Gourlet P; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
    Peptides; 1990; 11(4):773-7. PubMed ID: 2172943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes.
    Gourlet P; Woussen-Colle MC; Robberecht P; de Neef P; Cauvin A; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Eur J Biochem; 1991 Jan; 195(2):535-41. PubMed ID: 1997328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements for the occupancy of rat brain PACAP receptors and adenylate cyclase activation.
    Hou X; Vandermeers A; Gourlet P; Vandermeers-Piret MC; Robberecht P
    Neuropharmacology; 1994 Oct; 33(10):1189-95. PubMed ID: 7862254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a guanosine-nucleotide-binding-protein-coupled receptor for pituitary adenylate-cyclase-activating polypeptide on plasma membranes from rat brain.
    Schäfer H; Schwarzhoff R; Creutzfeldt W; Schmidt WE
    Eur J Biochem; 1991 Dec; 202(3):951-8. PubMed ID: 1662620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
    Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers A; Vandermeers-Piret MC; Robberecht P; Christophe J
    Biochim Biophys Acta; 1991 Jul; 1066(2):245-51. PubMed ID: 1649637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
    Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
    FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of pituitary adenylate cyclase-activating polypeptide receptors in Y-79 human retinoblastoma cells.
    Olianas MC; Ennas MG; Lampis G; Onali P
    J Neurochem; 1996 Sep; 67(3):1293-300. PubMed ID: 8752138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells.
    Eggenberger M; Born W; Zimmermann U; Lerner EA; Fischer JA; Muff R
    Neuropeptides; 1999 Apr; 33(2):107-14. PubMed ID: 10657479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pituitary adenylate cyclase-activating polypeptide].
    Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H
    Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of binding domains of pituitary adenylate cyclase activating polypeptide (PACAP) for its type 1 receptor by photoaffinity labeling.
    Cao YJ; Kojro E; Jasionowski M; Lankiewicz L; Grzonka Z; Fahrenholz F
    Ann N Y Acad Sci; 1998 Dec; 865():82-91. PubMed ID: 9928000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary adenylate cyclase activating polypeptide-mediated intracrine signaling in the testicular germ cells.
    Li M; Funahashi H; Mbikay M; Shioda S; Arimura A
    Endocrine; 2004 Feb; 23(1):59-75. PubMed ID: 15034198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Robberecht P
    Int J Pept Protein Res; 1996 Oct; 48(4):391-6. PubMed ID: 8919060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoaffinity labeling analysis of the interaction of pituitary adenylate-cyclase-activating polypeptide (PACAP) with the PACAP type I receptor.
    Cao YJ; Kojro E; Gimpl G; Jasionowski M; Kasprzykowski F; Lankiewicz L; Fahrenholz F
    Eur J Biochem; 1997 Mar; 244(2):400-6. PubMed ID: 9119005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors for pituitary adenylate cyclase-activating peptide in human liver.
    Guijarro LG; Rodriguez-Henche N; García-López E; Noguerales F; Dapena MA; Juarranz MG; Prieto JC
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2451-7. PubMed ID: 7629241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophysiotropic action of pituitary adenylate cyclase-activating polypeptide (PACAP) in the goldfish: immunohistochemical demonstration of PACAP in the pituitary, PACAP stimulation of growth hormone release from pituitary cells, and molecular cloning of pituitary type I PACAP receptor.
    Wong AO; Leung MY; Shea WL; Tse LY; Chang JP; Chow BK
    Endocrinology; 1998 Aug; 139(8):3465-79. PubMed ID: 9681497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.